{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"Complete hematologic response: Absence of detectable monoclonal protein in serum or urine by immunofixation electrophoresis, bone marrow biopsy with less than 5% plasma cells without clonal dominance of kappa or lambda isotype, and normal serum free light chain assay.\n\nPartial hematologic response: Amyloid patients have highly individualized measures of disease burden. For patients with detectable and quantifiable monoclonal marrow plasmacytosis, a reduction of 50% or more in plasma cells as a percentage of nucleated bone marrow cells. For patients with a detectable monoclonal peak on serum or urine protein electrophoresis, a reduction in the peak height of 50% or more. For patients with quantifiable urinary kappa or lambda chain concentration, a 50% reduction in daily light chain excretion (concentration x 24 hour urine volume). For patients with an elevated serum free light chain assay, reduction of 50% or more.","groups":[{"description":"Melphalan Lenalidomide Dexamethasone\n\ndexamethasone: 40 mg once weekly\n\nlenalidomide: 10 mg/day Days 1-21\n\nmelphalan: 5 mg/m2 Days 1-4","id":"OG000","title":"Melphalan Revlimid and Dexamethasone"}],"paramType":"NUMBER","populationDescription":"Participants who completed at least 3 cycles of treatment","reportingStatus":"POSTED","timeFrame":"one year","title":"Number of Participants With Hematologic Response","type":"PRIMARY","unitOfMeasure":"participants"}